We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Sarilumab (interleukin-6 receptor monoclonal antibody) for the treatment of pemphigus vulgaris.
- Authors
Andrew, Kashini; Dhariwal, Sukhjit K.; Szczecinska, Weronika
- Abstract
A brief review of pemphigus vulgaris. biomed dermatol 2017; 1: 7. 2 Atal S, Fatima Z. IL-6 inhibitors in the treatment of serious COVID-19: a promising therapy? Dear Editor, Pemphigus vulgaris (PV) is an autoimmune disorder characterized by blisters and erosions on the skin and mucosal surfaces. Interleukin (IL)-6 is a proinflammatory cytokine produced by CD4 SP + sp T helper cells and involved in the regulation of immune cells, and inhibiting its activity has led to new therapies for many inflammatory and autoimmune diseases.
- Subjects
PEMPHIGUS vulgaris; INTERLEUKIN-6 receptors; MONOCLONAL antibodies; RECEPTOR antibodies; IMMUNOGLOBULIN producing cells; AUTOIMMUNE diseases
- Publication
Clinical & Experimental Dermatology, 2023, Vol 48, Issue 9, p1055
- ISSN
0307-6938
- Publication type
Article
- DOI
10.1093/ced/llad173